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ABSTRACT 
The development of sensitive methods for observing individual bacterial 
cells in a population in experiment and natural environments is very crucial for 
rapid development of anti-mycobacterial drugs. This is because more pathogenic 
Mycobacteria are slow growing organisms, and therefore the screening 
compounds for anti-mycobacterial activity is slow and inefficient. Previously, 
studies have been done using fluorescent bacteria that expressing 13-
galactosidase (21 ), and luciferase (3) as a high screening format for anti-
microbial activity. However, one drawback of these systems is that substrates 
such as luciferin have to be added at the required time points to induce 
fluorescence. 
Recently Green Fluorescent Protein (GFP) has become a valuable and 
favourite tool as a marker of growth, which could be used for screening of anti-
microbial activity. This is because the marker can be visualised without 
interruption or termination of an experiment as is required with the detection of 
other commonly used markers such as B-galactosidase and luciferase. 
In this study a synthetic gene of GFP was constructed with mycobacteria 
codon bias using assembly PCR. A strong mycobacterial promoter from 65 kD 
mycobacterial heat shock protein was added to derive the expression. The 
constructed gene was cloned into vector and transformed into Escherichia coli. 
The ultimate aim is to use the recombinant plasmid carrying the synthetic gene 
with mycobacterial codon bias to create a recombinant fluorescing BCG, which 
2 
can be used as a tool for screening compound libraries for anti-mycobacterial 
activity. 
3 
CHAPTER 1 
1.0 INTRODUCTION 
1.1 REVIEW OF TUBERCULOSIS 
Tuberculosis has been present in the human population as old as human 
history. A fragment of the spinal column of on Egyptian mummy from 2400 BC 
showed definite pathological of tubercular decay. An ancient Greece philosopher, 
Hippocrates described a common illness that was known as pthisis. (33) It is 
believed that, pthisis is the same disease that nowadays called is tuberculosis. 
Over the centuries since Hippocrates, tuberculosis has been known as a major 
scourge of the human species, and other species as well. (33) In the first half of 
the 20th century, tuberculosis was known as 'consumption' or 'white plaque' and 
became the number one kUier in many populations (35). 
In 1720, the English physician Benjamin Marten was the first to 
conjecture, in his publication, A New Theory of Consumption, that TB could be 
caused by "wonderfully minute living creatures", which, once they had gained a 
foothold in the body, could generate the lesions and symptoms of the disease. 
(35). And, because of its infectious nature and usually long chronic course, 
tuberculosis had a great impact on the health and lives of many families. Worst 
still, until 1800s, there was no treatment for tuberculosis and the disease 
approved often cause death to the infected persons. (33) 
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In 1865, the French military doctor, Jean-Antoine Villemin, single-handedly 
demonstrated that consumption could be passed from humans to cattle and from 
cattle to rabbits (35). On the basis of this revolutionary evidence, he postulated a 
specific microorganism as the cause of the disease, finally laid to rest the 
centuries-old belief that consumption arose spontaneously in each affected 
organism. In 1882, Robert Koch discovered a staining technique that enabled 
him to discover the causative agent of tuberculosis and named it as M. 
tuberculosis (35). 
In 1940, Selman A. Waksman and his team were able to isolate an 
effective anti-TB antibiotic~ actinomycin, but this proved to be too toxic for use in 
humans or animals. However, in 1943, streptomycin was purified from 
Streptomyces griseus, which exerted maximal inhibition of Mycobacterium 
tuberculosis with relatively low toxicity. Following streptomycin, p-aminosalicylic 
acid (1949), isoniazid (1952), pyrazinamide (1954), cycloserine (1955), 
ethambutol (1962) and rifampin (rifampicin; 1963) were introduced as anti-TB 
agents (35). Aminoglycosides such as capreomycin, vancomycin, kanamycin and 
amikacin, and the newer quinolones (e.g. ofloxacin and ciprofloxacin) are also 
used, but only in drug resistant situations. Combinations of a J3-lactam antibiotic 
with a J3-lactamase inhibitor enhance treatment effectiveness, but the newer 
drugs, including the macrolides, have not had much of the clinical testing (35). 
Unfortunately, 50 years after the introduction of effective chemotherapy, 
TB remains, along with AlDS, the leading infectious cause of adult mortality in 
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the world, causing up to two million of deaths in every single year (30). The 
number of new TB cases (3ach year climbed 6% between 1997 and 1999 to 8.4 
million worldwide (31). And, nowadays, it is estimated that if the trend continued, 
there will be a total of 36 million deaths by 2020 each year (30). 
In 1993, World Health Organization declared tuberculosis as a global 
emergency, responsible for causing death of more youth and adults than any 
other pathogens. During 2001, a standard form for reporting surveillance data 
was sent to 21 0 countries requested the information about policy and practice in 
TB control, the number and types of TB cases notified in 2000, and the outcomes 
of treatment and retreatment for smear-positive cases registered in 1999 (29). 
Tuberculosis is a disease that caused by a grouped microorganism, which 
is known as Mycobacterium tuberculosis complex. The disease remains one of 
the world's most difficult problems, affecting one-third of the world population. 
And, among these, eight to ten million develop new active disease and caused 
more death per year worldwide than any other bacterial pathogens. Moreover, 
evidence showed tuberculosis is the greatest caused of death among women of 
reproductive age and it is estimated that 900 million women are currently infected 
and 2.5 million will develop active disease and one million will die (30). 
According to World Health Organization, more than 1.5 million 
tuberculosis cases occur annually in Sub-Saharan Africa, nearly three million 
cases occur in Southeast Asia and over 250000 cases in Eastern Europe (31). In 
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the United States the rate of tuberculosis infection had been declining steadily 
until 1984, when there was an increase (31 ). Numerous factors have been 
identified to account for the resurgence of tuberculosis in United States as well 
as in Europe and all over the world. These includes reactivation of the disease in 
the elderly, the prevalence of Human Immunodeficiency Virus (HIV) infection and 
AIDS, immigration of infected persons from countries where tuberculosis is 
prevalent, socio-economic decline in urban areas, erosion of the system for 
diagnosis and treatment of the disease, and the emergence of multidrug-resistant 
strains of Mycobacterium tuberculosis. (30) 
Because of these reasons, WHO estimates that eight million people get 
tuberculosis every year, of which 95% live in the developing country. 
Furthermore, AIDS or Autoimmune Deficiency Syndrome coexisting with of 
mycobaterial infection is bringing back tuberculosis into Western cities and 
seriously threatens health services in the developing country (35). In addition, it 
is believed that among HIV patients one in ten per year will develop active 
tuberculosis, while one i11 two or three tuberculin positive AIDS patients will 
develop active TB. (35) 
The situation is worsening because there has been no new class of 
antimycobacterial drugs introduced over the last 30 years (28). Furthermore, the 
treatment regimen consists of a combination of drugs, which must be taken over 
a period of 6 to 12 months (4). The length of the treatment often results in non-
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compliance when patients do not undertake the treatment properly. Improper 
treatments often result in bacteria to develop resistance to antibiotics. 
The emergence of multi-drug resistance occurs as a result of mutation. 
The mutation is not only dependent upon the presence of the drug. For example, 
when exposed to a single effective anti-tuberculosis medication, the predominant 
bacilli, sensitive bacilli are killed, while a few drug resistant mutants, likely to be a 
present if the bacterial population are large, will multiply freely (35). Because of 
these reasons, it is crucially important that support be given to research efforts 
devoted to developing an effective TB vaccine, shortening the amount of time 
required to ascertain drug sensitivities, improving the diagnosis of TB, and 
creating new, highly effective anti-TB medications (36). 
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CHAPTER2 
2.0 REVIEW OF LITERATURE 
Mycobacterium is a slow growing bacterium, which may takes anything 
between 2 to 8 weeks in order to grow. This will cause the screening of 
compounds for antimycobacterial activity by conventional microbiological 
methods to be extremely slow and inefficient (4). Because of that, new methods 
with high echnology need to be developed to allow high throughput screening of 
compound for antimycobacteria activity. Previously, fluorescent bacteria 
expressing J3-galactosidase (21) and luciferase (3) have been used in a high 
throughout screening format for anti-tuberculosis drug. 
The use of fluorescent recombinant mycobacterium expressing luciferase 
gene have been reported, but this method has certain disadvantages. This is 
because the substrate, luciferin, has to be added at the require time points to 
induce fluorescent (1 0). Thus this detection method require the distruption of 
cells, which therefore do not allow a single culture to be followed through from 
the beginning until the end (4). J3-galactosidase on the other hand is 
enzymatically active only when retained in the cytoplasm (13). 
In addition to in vitro assays, the screening system must include assays 
that can detect antimycobacterial activity of the test samples against 
mycobaterium inside the macrophages. The luciferase expressing recombinant 
mycobacteria system has been used in a macrophage based on the assay 
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system (3). Furthermore, a system utilizing mycobacteria expressing the 
Escherichia coli beta-galactosidase genes have also been used in the 
macrophage format (17). However these methods require extracts to be 
prepared and the addition of substrate, which increase, time and labour. While, 
Green Fluorescent Protein expressing recombinant mycobacteria have been 
successfully used in in-vitro assay for anti-mycobacterial assay. 
Green Fluorescent Protein (GFP) was discovered as a convenient reporter 
of cell viability (23), that have the ability to overcome these problems. The 
fluorescent protein has been shown to be useful in the development of 
recombinant mycobacteria for screening assay (9). However, the level of 
fluorescence emitted by these recombinant mycobacteria was found to be low 
and therefore decreasing sensitivity. This could be due to the fact that 
mycobacteria are GC rich organism, which may not express low GC rich genes. 
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2.1 PROPERTIES OF Mv~obacterium tuberculosis 
M. tuberculosis is a member of the closely related group of species, 
known as the Mycobacterium tuberculosis complex. Apart from M. tuberculosis 
this complex includes Mycobacterium bovis, Mycobacterium africanum and 
Mycobacterium microti. Apart from Mycobacterium microti, which affects voles 
and is of limited human pathogenicity, the other three can all cause human 
tuberculosis. The mycobacterial genome has been estimated to be around 3-5.5 
x 109 daltons. (8). Unlike the fast growing mycobacteria and organisms like 
Escherichia coli, Mycobacterium tuberculosis has only one rRNA operon. 
On the basis of growth rate, Mycobacterium can be divided into two 
groups of species, known as the Slow Growers and the Fast Growers. The Slow 
Growers tend to be associated with human or animal disease, while the Fast 
Growers tend to be non-pathogenic. They are widely distributed in soil and some 
marine environments (34). Over 300 species have been named. The complete 
genome sequence of the best-characterized strain of M. tuberculosis, H37Rv, 
has been determined and analysed in order to improve the understanding of the 
biology of this slow-growing pathogen and to help the development of new 
prophylactic and therapeutic interventions. (8). 
The genome comprises 4,411 ,529 base pairs, contains around 4,000 
genes, and has a very high guanine and cytosine content. (8). The GC content of 
the DNA of those mycob~cterial species studied varies from 66-71 of molecule 
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percentage. (34). M. tuberculosis differs radically from other bacteria in that a 
very large portion of its coding capacity is devoted to the production of enzymes 
involved in lipogenesis ard lipolysis, and to two new families of glycine-rich 
proteins with a repetitive structure that may represent a source of antigenic 
variation (8). 
Mycobacteria are Gram-positive non-motile, pleomorphic rods, related to 
the Actinomyces. Most mycobacteria are found in habitats such as water or soil. 
However, a few are intracellular pathogens of animals and humans. 
Mycobacterium tubercu/Qsis is a highly contagious, airborne, rod-shaped 
organism (bacillus) that thrives on oxygen, grows slowly and possesses a 'waxy' 
cell wall. It also an obligate aerobes that grow most successfully in tissues with 
high oxygen content. Mycobacteriums are facultative intracellular pathogens that 
usually multiply in the monpnuclear phagocytes. 
The cell walls are hydrophobic with high lipid content, and are often known 
as acid-fast bacilli. The cell wall's structure and function are not well understood 
but appear to allow the bacteria to survive within immune cells called 
macrophages, specialized cells that destroy bacteria and viruses. It is also 
provides the organism with a resistant barrier to many common drugs. 
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2.2 GREEN FLUORESCENT PROTEIN 
Green fluorescent protein, GFP, is a spontaneously fluorescent protein 
isolated from the Pacific jellyfish, Aequoria victoria (19). Its role is to transduce, 
by energy transfer, the blue chemiluminescence of another protein, aequorin, into 
green fluorescent light (25). The light is produced when energy is transferred 
from the Ca2+- activated photoprotein aequorin to green fluorescent protein (26). 
The molecular cloning of GFP eDNA (20) and the evidence that GFP can 
be expressed as a functional transgene (7) has opened exciting new avenues of 
investigation in cell, developmental and molecular biology. Fluorescent GFP has 
been expressed in bacteria (7), yeast (14), slime mold (18), plants (6), drosophila 
(12), zebrafish (24), and in mammalian cells (2). This protein function as a 
protein tag, as it tolerates N- and C-terminal fusion to a broad variety of proteins 
many of which have been shown to retain native function (18). 
Green Fluorescent Protein had become an important expression marker 
for monitoring gene expression and protein localization in vivo, in situ, and real 
time (15), and is useful fQr monitoring of bacteria in laboratory model systems 
and in actual environment (27). It is also attracting wide spread interest because 
of its tremendous potential for cell lineage determination and in-situ monitoring of 
cell growth and development. GFP expressing recombinant Mycobacterium have 
been used in vitro assays for screening compound for antimycobacterial activity 
(16). 
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Furthermore, these proteins are stable, species independent, do not 
require a substrate or cofactor and can be easily detected. The GFP marker can 
be visualized by using standard microscope equipped with commonly available 
fluorescent filter sets. In addition, green fluorescent protein has been proved to 
be a valuable tool for studying a variety of biological questions with living 
systems (7). 
GFP may be useful as a growth marker for mycobacteria as it may be 
detected at a very early stage of growth. This will lead to detection of 
antimycobacterial activity at an early stage without requiring colonies to form, 
which may take up 8 weeks. In addition, because of its cloning and commercial 
availability, the applications of GFP as a reporter gene have become prevalent in 
many studies (1 ). For example, some research demonstrated that the green 
recombinant Mycobacterium bovis BCG were clearly visualized by UV 
microscopy (27). This study proposed new method for monitoring BCG bacteria 
trafficking with recombinant BCG expressing Green Fluorescent Protein (27). 
Meanwhile, plasmid pBEN, containing the gene encoding a red-shifted, high-
intensity GFP mutant, was incorporated into Mycobacterium terrae {ATCC 
15755), and the GFP expression was observed by epifluorescence microscopy. 
In other studies, two green fluorescent protein (GFP) fusion vectors were 
constructed for use in Mycobacterium spp. The first plasmid facilitated 
quantification of mycobacterial promoter activity {11). The second vector 
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permited construction of translational fusions of mycobacterial proteins to GFP in 
order to study subcellular localization including protein secretion (11 ). Using this 
translational fusion construct, it was possible to show that a GFP fusion to the 
putative secreted M. tuberculosis protein ChaD was translocated to the 
extracellular milieu when cloned and expressed in Mycobacterium smegmatis 
(11). 
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CHAPTER3 
3.0 OBJECTIVE OF THE STUDY 
In this research, further enhancement of fluorescence was attempted 
through the construction of a synthetic gene of GFP that will be developed with 
mycobacterial codon bias and fused to a mycobacterial signal sequence to 
enable secretion of the protein into the medium. The ultimate aim in this research 
is to develop a recombinant plasmid that can be used to express GFP at an 
optimum level in BCG. This fluorescent recombinant BCG can then be used as a 
tool for rapid screening of compounds for antimycobacterial activity. The overall 
research strategy will be shown in the Figure 1. 
Fig. 1.0 Overall Research Strategy 
Oligos for Assembly PCR 
Perform Assembly PCR using appropriate I 
mix of upper and lower strands oligos t 
Product 
PCR using appropriate 
primer pairs 
Ndei-65kdPromoter-MPT63 Signal Sequence-GFP-Cla 
Clone into TOPO ~ 
Hin-Kpn-Eco-Ndei-65kdPromoter-MPT63 Signal Sequence-GFP-Cla-Eco 
Sequencing to confirm insert 
Future use for developing recombinant Mycobacteria 
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CHAPTER4 
4.0 MATERIALS AND METHOD 
4.1 MATERIALS 
The materials and reagents that were used in this project were listed as below, 
categorized by the product company. 
810-RAD 
The power supply for Agarose Gel electrophoresis. 
FERMENT AS 
Taq DNA Polymerase, deoxynucleotides triphosphates (dNTPs), MgCI2, 
(Concentration-1 Ox) PCR Reaction Buffer, PCR reaction buffer with ammonium 
sulphate, restriction enzyme and their respective 1 Ox buffers. 
INVITROGEN 
100bp DNA Ladder, TOPO TA Cloning® Kit 
PROMEGA 
Agarose, X-Gal, Tris Base, dATPs, 100 bp marker 
SIGMA 
Disodium EDTA 2H20 (Ethylene Diaminotetraacetic Acid), Bromophenol Blue 
AMNESCO 
N', N-Dimethylformamide (DMF) 
PRONADISA 
Tryptone, Yeast Extract 
MERCK 
Agar-agar 
SYSTEM 
Boric Acid 
BDH Chemicals Ltd. 
Ethanol (absolute), MgCI2~6 hydrate 
BOEHRINGER MANNHEifJI 
Expand™ High Fidelity PC.R System 
ROCHE 
1 Ox concentration PCR Reaction Buffer 
MILLIPORE 
DNA Gel Extraction Kit 
18 
4.1.1 Tris-borate-EDTA (TBE), pH 8, 10 X strength 
Table 1: The ingredient of reagents used in the preparation of TBE. 
Reagent Volume/weight 
Tris base 108 g 
Boric Acid 54g 
Na2EDTA.2H20 4.65g 
dH20 is added up to 1000 ml 
The solution was autoclaved and kept at room temperature. For agarose gel 
electrophoresis, the solutiQn was diluted to 0.5 X strength. In order to obtain 1000 
19 
ml of 0.5 X, 50 ml of 10 X TBE solutions will be diluted using 950 ml of distilled 
water. The solution had been reused twice. It is because reused of running buffer 
lead to increasing of pH and therefore reduce yields of DNA. In addition, in the 
absence of ions, electric~l conduction is minimal and the DNA migrates very 
slowly or not at all. In the high ion concentration the current conductance is so 
efficient, that a lot of heat is generated and the resulting the gel melt and DNA is 
denatured. 
4.1.2 Loading Buffer 
Table 2: The ingredient of reagents used in the preparation of loading buffer 
Reagent Volume/weight 
Gliserol (BDH chemicals) 3ml 
Bromophenol Blue (Sigma, USA) 0.03g 
The deionised-distilled water is being added to make up the end volume to 10 mi. 
The solution is being kept ;;lt 4°C. 
4.1.3 Preparation Of Ethidium Bromide 
10 f.lg/f.l1 of stock or working solution of 0.5 to 1.0 f.lQ/f.ll prepared by 
dilution of 1 00 J.11 of stock solution in the 500 f.ll of distilled water. The prepared 
solution was stored in the ~ark bottle because it is sensitive to the light. 
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4.1.4 Preparation of 100 bp marker (PROMEGA) 
Table 3: The ingredient of reagents used in the preparation of 1 OObp marker. 
Reagent Volume (J.LI) 
DNA ladder 20 
Loading buffer 20 
1X TRIS/EDTA (pH 7.6) 60 
The DNA ladder that provided by OMEGA was prepared by adding particular 
volume of loading buffer and 1XTRIS/EDTA (pH 7.6). The marker solution is kept 
at 4 °C. The marker is being used to determine the size of double stranded DNA. 
The ladder is consisting of 11 double-stranded DNA fragments with the size of 
100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 and 1500 bp. The 500 bp 
band is present at triple the intensity of the other fragments and served as a 
reference indicator while other fragment appear equal intensity on the gel. The 
loading volume used is 5 JJ.I. 
4.1.5 Preparation Of A Hind Ill marker (500 mgiJ.11) 
Table 4: The ingredient of reagents used in the preparation of A Hind Ill marker. 
Reagent Volume (J.LI) 
A. Hind Ill marker 20 
Loading buffer 20 
1X TRIS/EDTA (pH 7.6) 60 
The final concentration for the marker was 50 mg/J.L1. A Hindlll marker consist of 
564, 2027, 2322,4361,6557, 9416,23130 base pair in size. The marker must be 
incubated at 65°C for 10 minutes before used for first time usage. 
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4.1.6 Blue Orange &X Loading Dye (G190Al 
The blue orange 6X dye was supplied with the commercial markers. It has a 
composition of 15% Ficoll® 400, 0.03% Bromophenol Blue, 0.03% Xylene 
cyanol, 0.4o/o Orange G, 10 mM Tris-HCI (pH 7.5) and 50 mm EDTA. 
4.1. 7 1 0 X TE buffer (Tris 1 00 mM. EDT A 1 0 mM) 
I 
Table 5: The ingredient of reagents used in the preparation of 10 X TE buffer. 
Reagent Weight (g) 
Tris, pH 8.0 12.1 
EDTA 3.7 
Distilled water was added to 1 00 ml and the solution were autoclaved at 121 °C 
for 15 minutes. The solution was kept at room temperature. 1 X TAE was 
prepared, by diluting the solution with sterile water at particular volume. 
4.1.8 Preparation of Ethanol 70 °k <BDH Chemicals) 
Table 6: The ingredient of reagents used in the preparation of Ethanol70%. 
Reagent Volume (ml) 
Ethanol (Anal~r Grade) 70 
Sterile water 30 
To prepare 70 o/o ethanol concentration, 70 ml ethanol was diluted with 30 ml of 
sterile water. The solution was kept in the room temperature for not longer than 1 
year. 
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4.1.9 Preparation Of 0.1 M MgCI!.(BDH Chemicals) 
Table 7: The ingredient of reagents used in the preparation Of 0.1 M MgCI2 
Reagent Volume/weight 
MgCI2 2.03 g 
Sterile water 100 ml 
2.03 g of MgCI2 powdetr was added to 100 ml of distilled water before 
autoclaving. The solutions were kept at room temperature. 
4.1.1 0 Preparation Of 0.1 M CaCI2 (BDH Chemicals) 
Table 8: The ingredient of reagents used in the preparation Of 0.1 M CaCI2 
Reagent Volume/ weight 
CaCI2 2.03g 
Sterile water 100 ml 
2.03 g of CaCI2 dehydrate was added to 100 ml of distilled water before 
autoclaving. The solution was kept at room temperature. 
4.1.11 Preparation of Culture Media 
4.1.11.1 Luria-Bertani Broth 
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Table 9: The ingredient of reagents used in the preparation Of LB Broth. 
Reagent Volume/weight 
Bactotryptone 15 g 
Bacto Yeast extract 5g 
NaCI2 10 g 
dH20 make up to 1000 ml 
Ingredients were dissolved in 800 ml of distilled water and pH was adjusted to 
7.5. The volume was made up to 1000 ml with distilled water. The solutions were 
aliquoted into 5 or 10 ml per bottle. All media were autoclaved at 121°C for 15 
minutes, and allowed to cool to room temperature before addition of antibiotic or 
other substances if required. The broth was kept at room temperature. 
4.1.11.2 Luria-Bertani Agar 
Table 10: The ingredient of reagents used in the preparation Of LB Agar 
Reagent Volume/weight 
Bactotryptone 15 g 
Yeast extract 5g 
NaCI2 10 g 
dH20 make up to 1000 ml 
Agar 7.5 g 
24 
The ingredients were dissolved into 800 ml of water and pH was adjusted to 7 .2. 
The volume was then made up to 1 000 ml with water. The media were 
autoclaved at 121°C for 15 minutes, and allowed to cool to 50-55°C before 
addition of antibiotic or other substances if required. Ampicillin is usually added to 
a final concentration of 50 JlQ/ml. Then, the medium was plated out onto petri 
dish. The plates were incubated overnight as control for contamination or 
incomplete sterilization process. The plates were then kept in the cold room 
before used. 
